woman, possibly a doctor looking at the screen

Reduce risk and accelerate your clinical development in all kinds of hereditary diseases

De-risk your clinical trial

Whether you are running clinical trials in Parkinson’s disease, Alzheimer’s disease, cardiovascular disease or other hereditary diseases, you can reduce the risk of trial failure by identifying potential trial participants based on genotypic and phenotypic criteria.

Capitalize on our global partnership with Helix and sequence the DNA of every participant in your clinical trial using an exome assay developed by Helix.

Helix was the first laboratory to have an exome assay authorized by the FDA.

Examples of hereditary diseases and genes covered by the Helix exome assay

Hereditary disease
Atherosclerotic cardiovascular disease PCSK9
Autoimmune diseases CD40L
Alzheimer’s disease PSEN1
Cardiovascular disease TNNT2
Chronic kidney disease APOL1
Familial hypercholesterolemia PCSK9
Frontotemporal dementia GRN
Inflammatory diseases GLPR2
NASH (nonalcoholic steatohepatitis) PNPLA3
Parkinson’s disease SNCA
Type 2 diabetes mellitus GLP1R
The clinical trial assay developed by Helix – based on the Helix Laboratory Platform – allows you to customize the biomarkers of your clinical trial down to a single SNP or expand them to cover a multi-gene polygenic risk score. Furthermore, genetics experts at Helix can identify additional biomarkers that improve your inclusion and exclusion criteria.
Accelerate your clinical development

We are using a clinical trial exome assay developed by Helix. This technology was used to sequence the DNA of more than 500,000 individuals, with the data stored in a database linked to Electronic Health Records.

Helix and its health system partners continuously enroll more than 100,000 patients a year across a diverse mix of patient populations and continue to sequence their DNA using the Helix assay. This simplifies identification of potential participants for your clinical trial in hereditary diseases.

All individuals with sequencing data in the population genomics database have given permission for their health record and genomic data to be shared. Their consent does not just cover research purposes, it also allows Helix’s trusted health system partners to contact them about potential participation in clinical trials.

A phase II clinical trial of the phosphatidylserine targeting antibody, bavituximab in combination with pembrolizumab in patients with advanced hepatocellular carcinoma
Learn more about our partnership with Helix
Vital role of CDx in hereditary diseases

Vital role of CDx in hereditary diseases

Gain new insights into the role of CDx in the development of targeted therapeutics

One partnership, a global end-to-end solution for biopharma

Build on our expertise in global IVD development

Together, with our partner Helix, we provide biopharma companies like yours with a global solution for companion diagnostics (CDx). Our wealth of experience means we can navigate the regulatory path, satisfy regulatory requirements and drive your success.

Our teams have world-class experience in collaborative development of CDx with pharmaceutical companies throughout all phases of clinical trials. The FDA has granted us 11 Pre-Market Approvals (PMAs) for our CDx assays, each of them associated with a drug approval. These were all developed and clinically validated to support a new therapeutic.

QIAGEN assays have been approved by regulatory authorities around the world based on our competencies with global regulatory requirements, including IVDR. Build on our expertise in global clinical trial site setup and support for local testing. The clinical trial assay developed by Helix is based on the Helix Laboratory Platform and used in the US. Outside the US, we will use our whole exome assay to set up labs in territories where you require local clinical trial testing.